Value of Triglyceride Glucose Index in Prediction of Cardiac Outcomes in Patients With Acute Coronary Syndrome

Sponsor
Sohag University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05158231
Collaborator
(none)
400
1
6
66.9

Study Details

Study Description

Brief Summary

Triglyceride glucose index and a reliable alternative marker of insulin resistance and an independent predictor of major adverse cardiovascular events (MACEs), which was defined as the composite of total death, myocardial infarction, coronary revascularization, stroke, and hospitalization because of heart failure.

We hypothesis that there is a relation between prediction of MACE in acute coronary syndrome patients and between triglyceride glucose index.

Detailed Description

Cardiovascular diseases, particularly coronary artery disease (CAD), is considered as a main cause of death and disability in the developed countries as its responsible for about 1 in every 5 deaths In the last few years.

Acute coronary syndrome (ACS), which is the most severe ischemic heart disease including Non-ST-elevation myocardial infarction (NSTEMI), ST-elevation MI (STEMI), and unstable angina has been one of the leading causes of death worldwide which leads to a large social and economic burden.

It has been well recognized that the development of (CAD) is driven by multiple factors including glycemic abnormality and lipid disorders.

Insulin resistance (IR) is a key metabolic abnormality leading to the development of T2DM, and recent studies have also found that it could independently predict the development of cardiovascular disease (CVD). Hyperinsulinemic-Euglycemic Clamp (HIEC), as the gold standard for the diagnosis of insulin resistance, is very difficult to be carried out in clinical work due to its difficulty of operation and equipment requirements.

Triglyceride and glucose index (TyG index) was one of the alternative methods for evaluating insulin resistance and is a novel marker Unlike the homeostasis model assessment and quantitative insulin sensitivity check index, insulin is not included in the TyG index and a reliable alternative marker of insulin resistance and an independent predictor of major adverse cardiovascular events (MACEs), which was defined as the composite of total death, myocardial infarction, coronary revascularization, stroke, and hospitalization because of heart failure.

The TyG index was calculated as the ln (fasting triglyceride level [mg/dL] × fasting glucose level [mg/dL]/2) Normal cut-off values reported for the TyG in the literature are roughly around 4 and 8.

Aim of the work

To study the value of triglyceride glucose index as a short term predictor of MACE in diabetic and non diabetic patients presented by Acute coronary syndrome.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
400 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Value of Triglyceride Glucose Index in Prediction of Cardiac Outcomes in Patients With Acute Coronary Syndrome
Anticipated Study Start Date :
Dec 20, 2021
Anticipated Primary Completion Date :
May 20, 2022
Anticipated Study Completion Date :
Jun 20, 2022

Outcome Measures

Primary Outcome Measures

  1. Triglyceride glucose index [6months]

    Prediction of cardiac outcomes in acute coronary syndrome patients

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • acute coronary syndrome patients
Exclusion Criteria:
  • With acute infectious disease, rheumatic disease, hematological disease, or neoplastic disease.

  • With severe valvulopathy or cardiomyopathy

  • Lacking clinical or follow-up data.

  • suspected familial hypertriglyceridemia

Contacts and Locations

Locations

Site City State Country Postal Code
1 Sohag university Sohag Egypt 82515

Sponsors and Collaborators

  • Sohag University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Mohamed Ali Taha, Resident doctor at internal medicine department ,sohag university hospitals, Sohag University
ClinicalTrials.gov Identifier:
NCT05158231
Other Study ID Numbers:
  • ethics@med.sohag.edu.eg
First Posted:
Dec 15, 2021
Last Update Posted:
Dec 15, 2021
Last Verified:
Dec 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 15, 2021